Recent Updates
Recently added Catalysts
TTRX Positive Sentiment

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Turn Therapeutics reported third-quarter 2026 financial results and corporate updates. The company highlighted encouraging response rates in the full atopic dermatitis trial population from its Stage 1/Phase 2a study. These findings support the continued development of its targeted, non-systemic therapies for inflammatory skin diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Encouraging results in atopic dermatitis trial population.
  • Corporate updates indicate progress in development.
  • Financial results show stability for the company.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~20 mo
Low dilution risk
Lead asset
GX-03
Phase 2 · Eczema Atopic Dermatitis

Full Press Release Details

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and nine months ended September 30, 2026. Additional Stage 1/Phase 2a results show encouraging response in the full atopic dermatitis trial population In October 2026, Turn Therapeutics reported additional res

Frequently Asked Questions

What were the key updates from Turn Therapeutics?

Turn Therapeutics reported positive results in their atopic dermatitis trial.

When did Turn Therapeutics report their Q3 financial results?

The financial results were reported for the three and nine months ended September 30, 2026.

What is the focus of Turn Therapeutics' therapies?

The company develops targeted therapies for inflammatory and infectious skin diseases.

What stage are Turn Therapeutics' clinical trials in?

The trials are currently in Stage 1/Phase 2a.

ShareAdd on Google
Tags: TTRX Turn Therapeutics atopic dermatitis financial results clinical-stage biotechnology
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$10M liquidity · $1M/mo burn
~20 mo
Low dilution risk
Lead asset
GX-03Phase 2
Eczema Atopic Dermatitis →